|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Dr. Christopher R. Anzalone Ph.D.||CEO, President & Director||1,65M||996,46k||1969|
|Mr. Kenneth A. Myszkowski||Chief Financial Officer||761,55k||N/D||1966|
|Mr. Patrick O'Brien J.D., PharmD||COO, General Counsel & Secretary||749,86k||172,2k||1964|
|Dr. James C. Hamilton M.D., MBA||Chief of Discovery & Translational Medicine||676,81k||N/D||1978|
|Ms. Tracie Oliver||Chief Commercial Officer||449,58k||N/D||N/D|
|Dr. Mark M. Davis Ph.D.||Founder and Founder & Director of Insert Therapeutics Inc & Calando||N/D||N/D||N/D|
|Dr. Vincent Anzalone CFA||Head of Investor Relations & VP||N/D||N/D||N/D|
|Mr. Howard Lovy||Director of Communications||N/D||N/D||N/D|
|Dr. Mark Seefeld||Head of Toxicology & VP||N/D||N/D||1954|
|Dr. Javier San Martin M.D.||Chief Medical Officer||658,48k||N/D||1965|
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.
L'ISS Governance QualityScore di Arrowhead Pharmaceuticals, Inc. al 1 dicembre 2023 è 4. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 8; diritti degli azionisti: 1; retribuzione: 3.